Big Pharma Pipelines and more DDWell heres
Roche Pipeline novartis pipeline Lu-PSMA-617 is Endocyte's 2.1b buyout drug.
What's clear enough is that Big Pharma has their pipelines for bladder, lung, prostate, head/neck.. through 2022 and beyond.. alot of regulatory approvals for these drugs are coming and big pharma wants to see a return on their investments.
So lets cut the cra* with any talk about this so called open market.. big money has been spent on lead assets not called TLD-1433.... yet.
The key is finding that company that 'needs' a drug.. with the global connections and capital to make it happen..
That's how i got to Medtronic......a devices company.... We know Bladder is 100% Theralase's and should get full accolades. Honestly.... GBM should be all ours too.. knock out top two most expensive cancers in Canada... plus full accolades of blood brain barrier.. a true feather in the cap of our scientists..and textbooks for 100 years to come.
Where it gets interesting globally for me... it's peripheral lung tumours... it's absolutely clear to me the Navigate trial done by Medtronic Navigate done Nov 1 2019
1388 patients in 37 Hospitals Globally... USA, Austria, Denmark, France, Italy, Spain and UK
The Navablate is Medtronics attempt to use thermoabalation to 'treat lung cancer' 30 patients in Hong Kong and UK
Navablate Aug 2020
Thermoabalation IMO is referring to 'Photothermal ablation... has it's problems.
Review mentioning TLD-1433
Maybe reach out to this fellow...??, seems like a smart chap maybe another addition to an all-star cast on Theralase? Remember when we added people to TLT..
Michael R. Hamblin Ph.D. was Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital, Associate Professor of Dermatology, Harvard Medical School, affiliated faculty at the University of Johannesburg, South Africa. His research concerns photodynamic therapy and photobiomodulation. He has published > 480 peerreviewed articles, 25 textbooks including 13 SPIE proceedings. His hfactor is 102 with > 41 700 citations. He is EditorinChief of “Photobiomodulation, Photomedicine and Laser Surgery”. Honors include Fellow of SPIE 2011, 1st Endre Mester Lifetime Achievement Award NAALT 2017, Outstanding Career Award Dose Response Society, 1st Ali Javan award Photobiomodulation Basic Science Research from WALT 2018.
And finally why I think a JV with Medtronic leveraging the Innovation Centre opening 2020 is crucial.
Because technology (money) never sleeps pal.
Nano and PDT in China
Roger.. dont sit on your laurels... just when you think you have the goods and drink that coffee. technology and progress have a way of catching up.
It's like I posted 'convergent evolution' convergent evolution
In evolutionary biology, convergent evolution is the process whereby organisms not closely related (not monophyletic), independently evolve similar traits as a result of having to adapt to similar environments or ecological niches.
It is the opposite of divergent evolution, where related species evolve different traits.
On a molecular level, this can happen due to random mutation unrelated to adaptive changes; see long branch attraction.
In cultural evolution, convergent evolution is the development of similar cultural adaptations to similar environmental conditions by different peoples with different ancestral cultures.
Right now we are in the 4th industrial age... 'micro-machines' and 'small molecules'
Being 1st is everything..... in discovery, adoption and proliferation...
Ok that' about it today.